Talking Points From Penn Conference October 24, 2014

(This is taken directly from a post of the ACOR.ORG  Listserv).

Date:    Wed, 29 Oct 2014 13:08:06 -0400

From:    Jamie Lacroix <jamie.lacroix@CARINGFORCARCINOID.ORG>

Subject: Re: PENN Conf - NEW treatment options


Thank you so much for posting all of these great notes. This project, and two others, are actually being funded by the Caring for Carcinoid Foundation. We are posting more info on our website in the coming days, but as a preview, here are some more notes about each of the projects. A treatment that uses the body’s own immune system to fight cancer, immunotherapy has led to dramatic results for some patients with other forms of cancer. We are eager to test the potential of immune-based therapy to provide similar breakthroughs for patients with neuroendocrine cancers and have brought leading IMT experts on board to do so. Through a clinical trial and the development of breakthrough IMT technology, we will be focusing on the effects of immunotherapy for carcinoid and pancreatic neuroendocrine tumors.


The first project will engage the team that developed a breakthrough IMT technology to specifically target neuroendocrine tumors. This will include leading IMT expert Dr. Carl June, and neuroendocrine tumor researcher Dr. Xianxin Hua, both from the University of Pennsylvania. They will modify CAR T-cells to target and kill neuroendocrine tumor cells, a method that has had dramatic results in patients with other cancers. Success in this project could pave the way for trials of this breakthrough technology for neuroendocrine cancers.


The second project consists of conducting a clinical trial of two IMT therapies in pancreatic and carcinoid neuroendocrine patients. This project includes a multidisciplinary team led by Dr. Pamela Kunz from Stanford University, and consists of a clinical trial for carcinoid and pancreatic neuroendocrine tumor patients, combining two immunotherapy drugs that are in clinical trials for other cancers. An innovative delivery technique will also be tested to reduce the risk of adverse effects.


The third project studies the immune characteristics of neuroendocrine tumors to guide CFCF's testing of IMT treatments. This piece is essential to maximizing the chances of success in both other IMT projects. CFCF is inviting immunology experts to systematically characterize neuroendocrine tumors’ immune features and genomes, and multiple grants will be awarded to study and profile these tumors.